Table 3.
Source of early myeloid-derived suppressor cells at specified post-transplantation time points.
| Patient ID | E/R | HDMC/LDMC | Distinguishable HLA | PT time point | eMDSCs Recipient (%) | eMDSCs Donor (%) | Mixed Chimerism present |
|---|---|---|---|---|---|---|---|
| 225-19 | E | HDMC | Recipient is A3+ | PT-Day30 | 1 | 99 | Yes |
| HDMC | PT-Day60 | 1 | 99 | Yes | |||
| HDMC | PT-Day180 | 1 | 99 | Yes | |||
| 225-43 | E | HDMC | Donor is A2+ | PT-Day30 | 76 | 24 | Yes |
| HDMC | PT-Day100 | 85 | 15 | Yes | |||
| HDMC | PT-Day180 | 82 | 18 | Yes | |||
| 225-51 | E | HDMC | Donor is A2+ | PT-Day60 | 96 | 4 | Yes |
| HDMC | PT-Day100 | 98 | 2 | Yes | |||
| HDMC | PT-Day180 | 94 | 6 | Yes | |||
| 225-44 | E | HDMC | Donor is A2+ | PT-Day30 | 50 | 50 | Yes |
| HDMC | PT-Day60 | 99 | 1 | Yes | |||
| HDMC | PT-Day100 | 91 | 9 | Yes | |||
| HDMC | PT-Day180 | 84 | 16 | Yes | |||
| 225-10 | R | LDMC | Donor is A3+ | PT-Day30 | 100 | 0 | No |
| LDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| 225-52 | R | LDMC | Donor is A3+ | PT-Day30 | 100 | 0 | No |
| LDMC | PT-Day60 | 100 | 0 | No | |||
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No | |||
| 225-55 | R | LDMC | Donor is A2+ | PT-Day60 | 100 | 0 | No |
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No | |||
| 225-36 | R | HDMC | Donor is A2+ | PT-Day30 | 56 | 44 | Yes |
| HDMC | PT-Day60 | 98 | 2 | Yes | |||
| LDMC | PT-Day100 | 99 | 1 | Yes | |||
| LDMC | PT-Day180 | 99 | 1 | Yes | |||
| 225-40 | R | HDMC | Donor is A2+ | PT-Day30 | 0 | 100 | No |
| LDMC | PT-Day100 | 100 | 0 | No | |||
| LDMC | PT-Day180 | 100 | 0 | No |
Table showing the source of eMDSCs at HDMC and LDMC time points. High chimerism in eMDSCs observed in HDMC as compared to LDMC groups (chi-square =17.099; P< 0.00001, Yates correction applied).
E, engrafted; R, Rejected; HDMC, high donor myeloid chimerism; LDMC, low donor myeloid chimerism; PT, post-transplant; eMDSCs, early myeloid-derived suppressor cells.